## Core Concept
The maximum tolerated dose (MTD) of a new drug is the highest dose that can be given to patients without causing unacceptable side effects. This concept is crucial in the development of new drugs, particularly in the field of oncology and toxicology. The MTD is determined through a series of clinical trials.

## Why the Correct Answer is Right
The correct answer, **Phase I clinical trials**, is where the MTD of a new drug is primarily evaluated. Phase I trials are the first stage of testing in human subjects and are primarily focused on assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. These trials involve a small number of participants and use a dose escalation design to find the MTD.

## Why Each Wrong Option is Incorrect
* **Option A (Phase II):** Phase II trials are performed on larger groups (20-300) and are aimed at determining the efficacy of the drug as well as continuing to assess its safety. The MTD would have already been determined before these trials begin.
* **Option B (Phase III):** Phase III trials are large-scale trials (300–3,000 or more participants) that seek to be the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. Given that the MTD is already known, the focus here is on efficacy and side effect profile comparison rather than dose finding.
* **Option D (Preclinical trials):** Preclinical trials or studies are conducted in vitro (in a lab dish) or in vivo (in animals) and are used to determine a starting dose for the first-in-human trials (Phase I) but do not evaluate the MTD in humans.

## Clinical Pearl / High-Yield Fact
A key point to remember is that the MTD is not necessarily the therapeutic dose but rather the dose at which the drug can be tolerated without causing unacceptable side effects. The actual therapeutic dose might be lower and is determined based on efficacy and safety profiles in later phases of clinical trials.

## Correct Answer: C. Phase I.